

Glioma

Recurrent

High Grade

Pre- Avastin

BRAF Mutation

FGFR1-3
Alteration

Surgical
Procedural
Candidates

[BRN0048](#)
[Phase I, First-In-Human, Multicenter, Open-Label Study of ABM-1310, Administered Orally in Adult Patients with Advanced Solid Tumors](#)

PI: Nagpal
Sponsor: ABM Therapeutics, Inc.

BRN0056
Phase I/II Dose-Escalation Study of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

PI: Nagpal
Sponsor: VBI Vaccines Inc.

BRN0054
Phase II Pemigatinib in Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

PI: Lim
Sponsor: Incyte Corporation

BRN0057
Open Label Prospective Pilot Study to Evaluate the Safety & Effectiveness of the NaviFUS System in Conjunction w/ a Standard Treatment Regimen of Bevacizumab (BEV) in Recurrent Glioblastoma

PI: Airan
Sponsor: NaviFUS US LLC

BRN0042
Phase II/III Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

PI: Recht
Sponsor: Global Coalition for Adaptive Research

[CCT5061](#)
[Phase I Locoregionally \(LR\) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells \(B7-H3CART\) in Recurrent Glioblastoma Multiforme \(GBM\)](#)

PI: Thomas
Sponsor: Stanford University








[BRN0045](#)
[Phase I/II Exablate Type 2 for BBBD With Microbubble Resonators in Tx of rGBM in Carboplatin Mono Treatment](#)

PI: Nagpal
Sponsor: InSightec, Inc.

[BRN0049](#)
[Phase Ib Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 \(Nivolumab\), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 \(Nivolumab Plus Ipilimumab\) in Surgically Accessible Glioblastoma](#)

PI: Lim
Sponsor: Dana Farber Cancer Institute

KEY

	Pending		Optional Path		Extension Study
	Open for Enrollment	Link	Trial Posting		Immunotherapy
	Observational Study		Enrollment on Hold		